Atara gets EC approval for Ebvallo in EBV+ PTLD; board changes announced

Atara Biotherapeutics, Inc.

EC granted marketing authorization for Ebvallo (tabelecleucel) as monotherapy for relapsed/refractory EBV+ PTLD in adult/pediatric patients 2+ years.
Approval applies to all 27 EU member states plus Iceland, Norway, and Liechtenstein.
Directors Ronald C. Renaud and Roy Baynes resigned effective Dec 19, 2022; Carol D. Gallagher appointed Chair.
Board size reduced from ten to eight directors.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Carol D. Gallagher

Chair of the Board

ATRA · Atara Biotherapeutics, Inc.

Effective: 2022-12-19
Filed: December 19, 2022, 6:59 PM ET

In addition, effective as of December 19, 2022, the Board appointed Carol D. Gallagher, Pharm D., an independent member of the Board, to succeed Mr. Renaud as Chair of the Board and, in accordance with Section 16 of the Company’s Second Amended and Restated Bylaws, reduced the number of directors on the Board from ten to eight directors.

Departed

Roy Baynes

Director

ATRA · Atara Biotherapeutics, Inc.

Effective: 2022-12-19
Filed: December 19, 2022, 6:59 PM ET

Also on December 16, 2022, Roy Baynes notified the Company of his resignation from the Board, effective as of December 19, 2022.

Departed

Ronald C. Renaud

Director

ATRA · Atara Biotherapeutics, Inc.

Effective: 2022-12-19
Successor: Carol D. Gallagher
Filed: December 19, 2022, 6:59 PM ET

On December 16, 2022, Ronald C. Renaud notified Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), of his resignation from the Board of Directors of the Company (the “Board”), effective as of December 19, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Carol D. Gallagher was appointed as Chair of the Board at Atara Biotherapeutics, Inc..

Action: appointed
Role: Chair of the Board

Exact text from the filing

In addition, effective as of December 19, 2022, the Board appointed Carol D. Gallagher, Pharm D., an independent member of the Board, to succeed Mr. Renaud as Chair of the Board and, in accordance with Section 16 of the Company’s Second Amended and Restated Bylaws, reduced the number of directors on the Board from ten to eight directors.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Roy Baynes resigned as Director at Atara Biotherapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

Also on December 16, 2022, Roy Baynes notified the Company of his resignation from the Board, effective as of December 19, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ronald C. Renaud resigned as Director at Atara Biotherapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On December 16, 2022, Ronald C. Renaud notified Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), of his resignation from the Board of Directors of the Company (the “Board”), effective as of December 19, 2022.

View on SEC.gov

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-307898

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.